SCHEMBL4333674

SCHEMBL4333674

COc1cc(Nc2ccn3nc(-c4cc5ccccc5o4)cc3n2)cc(OC)c1OC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 4/20 0.44
F2RL3 Q96RI0 1/20 0.41
KDR P35968 2/20 0.41
FLT1 P17948 1/20 0.41
FLT4 P35916 1/20 0.41
IGF1R P08069 5/20 0.41
POLB P06746 2/20 0.40
RAD52 P43351 1/20 0.40
FLT3 P36888 1/20 0.40
PIK3CG P48736 1/20 0.40
EGFR P00533 1/20 0.39
INSR P06213 1/20 0.39
MET P08581 1/20 0.39
CDK2 P24941 1/20 0.39
TEK Q02763 1/20 0.39
TUBB4A P04350 1/20 0.39
TUBB P07437 1/20 0.39
TUBA3C P0DPH7 1/20 0.39
TUBA1B P68363 1/20 0.39
TUBA4A P68366 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4338921 0.85 CSNK2A1 (0.45) F2RL3KDM4EJAK2
SCHEMBL4333664 0.80 PIK3CG (0.57) BRAFKDRFLT1FLT4IGF1R
SCHEMBL4559505 0.77 KCNN3 (0.39) F2RL3KDREGFRCDK2KDM4E
SCHEMBL4342462 0.76 CSNK2A1 (0.38) F2RL3EGFRKDM4E
SCHEMBL4595119 0.73 MKNK1 (0.56) F2RL3KDM4E
SCHEMBL4342512 0.71 TUBB4A (0.40) BRAFF2RL3KDRFLT1FLT4
SCHEMBL4336105 0.71 MKNK1 (0.56) F2RL3KDM4E
SCHEMBL12635191 0.68 MAOB (0.67) KDM4E
SCHEMBL11672123 0.68 CALCRL (0.67) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL6900559 0.68 BRAF (0.59) BRAFKDRFLT1FLT4IGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2049539-A1 PYRAZOLOPYRIMIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME. Bayer Schering Pharma Aktiengesellschaft (DE) 2009-04-22 EP claimed
US-20080039455-A1 PYRAZOLOPYRIMIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME BAYER INTELLECTUAL PROPERTY GMBH (DE) 2008-02-14 US claimed
EP-1873157-A1 Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same Bayer Schering Pharma Aktiengesellschaft (DE) 2008-01-02 EP claimed
WO-2007147647-A1 PYRAZOLOPYRIMIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME. BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-12-27 WO claimed
US-20080039455-A1 PYRAZOLOPYRIMIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME BAYER INTELLECTUAL PROPERTY GMBH (DE) 2008-02-14 US disclosed
EP-1873157-A1 Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same Bayer Schering Pharma Aktiengesellschaft (DE) 2008-01-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039455-A1 PYRAZOLOPYRIMIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME DPYD, FLT1, PDXK BRAF 554/4885F2RL3 2753/4885KDR 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.